Saturday 17 October 2026
Export PBH’s income statement to Excel — free account
Prestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025. In the quarter to June 2026, revenue grew 6.48%, EPS fell 36.5%, free cash flow fell 14.2% and total debt rose 100.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
49.92
0.72
+1.46%
Follow PBH
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 9 | 9 | 6 | 6 | 7 | 9 | 5 | 6 | 3 |
P/E ratio |
15.04 | 19.90 | 17.03 | 0.00 | 12.98 | 13.44 | 13.01 | 0.00 | 5.16 | 42.09 |
Altman Z-Score |
2.48 | 3.06 | 2.64 | 1.85 | 1.87 | 1.67 | 1.43 | 1.09 | 1.21 | 1.17 |
P/S ratio |
2.64 | 3.76 | 3.17 | 2.77 | 2.45 | 2.35 | 1.93 | 1.57 | 1.68 | 3.34 |
Altman Z″-Score (non-manufacturers) |
4.04 | 4.04 | 3.57 | 2.30 | 2.74 | 2.51 | 2.27 | 1.62 | 1.82 | 1.25 |
P/FCF ratio |
11.65 | 17.56 | 14.90 | 14.08 | 10.63 | 10.37 | 9.18 | 8.55 | 8.87 | 20.19 |
Beneish M-Score |
(2.53) | (2.41) | (2.42) | (2.73) | (2.34) | (2.74) | (2.55) | (2.75) | (2.23) | (2.14) |
P/Operating CF |
67.04 | 69.08 | 53.31 | 52.97 | 42.15 | 37.46 | 33.15 | 30.05 | 32.19 | 391.19 |
P/B ratio |
1.52 | 2.33 | 2.15 | 2.16 | 1.69 | 1.63 | 1.59 | 1.39 | 1.49 | 3.58 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.52 | 4.57 | 4.14 | 3.92 | 3.79 | 3.90 | 3.64 | 3.39 | 3.57 | 5.79 |
EV/EBITDA |
11.18 | 14.10 | 12.31 | 303.52 | 11.26 | 11.05 | 10.83 | 31.44 | 14.56 | 21.26 |
EV/Operating CF |
14.87 | 20.67 | 18.70 | 19.26 | 15.87 | 15.60 | 16.16 | 17.48 | 17.71 | 34.33 |
EV/FCF |
15.54 | 21.36 | 19.45 | 19.93 | 16.48 | 17.23 | 17.32 | 18.50 | 18.83 | 35.01 |
Quick Ratio |
2.12 | 2.74 | 1.91 | 1.40 | 1.16 | 1.20 | 1.64 | 1.39 | 1.41 | 1.10 |
Current Ratio |
3.57 | 4.20 | 3.20 | 2.44 | 2.04 | 2.21 | 2.44 | 2.37 | 2.46 | 2.06 |
Net Debt/EBITDA |
2.77 | 2.48 | 2.85 | 88.44 | 3.97 | 4.37 | 5.06 | 16.83 | 7.67 | 8.96 |
Debt/Assets |
28.96% | 29.77% | 33.93% | 40.18% | 40.35% | 43.35% | 49.37% | 52.27% | 53.00% | 56.09% |
Debt/Equity |
0.54 | 0.55 | 0.68 | 0.93 | 0.94 | 1.09 | 1.48 | 1.64 | 1.69 | 2.67 |
Asset Turnover |
0.32 | 0.34 | 0.34 | 0.32 | 0.31 | 0.27 | 0.28 | 0.27 | 0.27 | 0.26 |
Operating CF/Net income |
1.35 | 1.17 | 1.19 | (2.79) | 1.27 | 1.43 | 1.53 | (5.29) | 0.62 | 2.14 |
Capex/Depreciation |
(0.34) | (0.26) | (0.27) | (0.21) | (0.27) | (0.63) | (0.44) | (0.28) | (0.31) | (0.08) |
Interest Coverage |
7.31 | 7.07 | 5.10 | (0.32) | 5.13 | 3.61 | 3.03 | 0.64 | 2.03 | 2.20 |
| 10.22% | 12.30% | 13.50% | (5.44%) | 13.99% | 13.02% | 12.55% | (3.15%) | 33.94% | 8.86% | |
| 5.52% | 6.39% | 6.28% | (2.34%) | 5.79% | 4.74% | 4.09% | (0.99%) | 8.85% | 2.02% | |
ROIC |
6.82% | 7.65% | 7.83% | (0.51%) | 6.80% | 6.61% | 6.47% | 1.47% | 4.29% | 4.32% |
Return on Tangible Assets |
44.03% | 51.56% | 62.58% | (27.30%) | 92.87% | 75.63% | 52.36% | (15.90%) | 145.84% | 31.12% |
Average Days of Receivables |
64.34 | 62.33 | 57.34 | 54.06 | 46.79 | 44.37 | 57.05 | 55.66 | 49.39 | 56.58 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
24.36% | 23.20% | 23.06% | 22.38% | 24.37% | 23.71% | 24.54% | 23.86% | 22.35% | 24.66% |
Intangible Assets out of Total Assets |
0.82 | 0.83 | 0.86 | 0.86 | 0.89 | 0.89 | 0.87 | 0.90 | 0.90 | 0.90 |
Share Based Compensation of Revenue |
1.00% | 0.98% | 1.24% | 1.10% | 0.83% | 0.91% | 0.79% | 0.76% | 0.86% | 0.92% |
Graham Net Nets |
(0.41) | (0.26) | (0.36) | (0.48) | (0.68) | (0.81) | (1.06) | (1.34) | (1.30) | (0.94) |
Graham Number |
58.76 | 59.91 | 56.13 | 0.00 | 53.68 | 44.68 | 38.27 | 0.00 | 56.54 | 21.47 |
Earnings Yield |
6.65% | 5.03% | 5.87% | (2.65%) | 7.71% | 7.44% | 7.69% | (2.39%) | 19.39% | 2.38% |
Free Cash Flow Yield |
8.58% | 5.69% | 6.71% | 7.10% | 9.41% | 9.64% | 10.89% | 11.70% | 11.28% | 4.95% |
Revenue per Share |
22.47 | 22.89 | 22.62 | 22.60 | 21.62 | 18.79 | 18.99 | 18.74 | 19.61 | 16.65 |
Operating CF per Share |
5.32 | 5.06 | 5.00 | 4.60 | 5.17 | 4.69 | 4.28 | 3.64 | 3.96 | 2.81 |
Capex per Share |
(0.23) | (0.17) | (0.19) | (0.16) | (0.19) | (0.44) | (0.29) | (0.20) | (0.24) | (0.05) |
Free Cash Flow per Share |
5.09 | 4.90 | 4.81 | 4.45 | 4.98 | 4.25 | 3.99 | 3.43 | 3.72 | 2.75 |
Cash per Share |
1.32 | 1.97 | 0.93 | 1.17 | 0.54 | 0.64 | 1.87 | 0.53 | 0.61 | 0.79 |
Shareholders Equity per Share |
38.95 | 36.92 | 33.26 | 29.01 | 31.39 | 27.05 | 23.09 | 21.05 | 22.20 | 15.53 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
38.95 | 36.92 | 33.26 | 29.01 | 31.39 | 27.05 | 23.09 | 21.05 | 22.20 | 15.53 |
Free Cash Flow |
246.45 | 243.29 | 239.38 | 221.93 | 250.28 | 213.36 | 202.56 | 178.80 | 197.58 | 145.78 |
Working Capital |
310.56 | 341.71 | 258.00 | 231.03 | 149.85 | 147.70 | 215.77 | 173.96 | 180.28 | 172.43 |
Capital Expenditures |
(11.18) | (8.22) | (9.55) | (7.78) | (9.64) | (22.24) | (14.56) | (10.48) | (12.53) | (2.89) |
Net Current Asset Value |
(1,175.31) | (1,118.99) | (1,288.29) | (1,514.90) | (1,799.80) | (1,801.14) | (1,977.28) | (2,044.27) | (2,278.52) | (2,754.36) |
EV/EBIT |
12.38 | 15.43 | 13.60 | 0.00 | 12.50 | 12.36 | 12.05 | 49.00 | 17.27 | 24.82 |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 |
Price to Operating Income |
9.28 | 12.69 | 10.42 | 0.00 | 8.06 | 7.44 | 6.39 | 22.64 | 8.13 | 14.31 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.27 | 0.43 | 0.47 | 0.53 | 0.51 | 0.50 | 0.59 | 0.74 | 0.76 | 0.68 |
Cash ROIC |
8.32% | 8.26% | 8.47% | 7.78% | 8.11% | 7.42% | 6.75% | 6.12% | 6.17% | 4.77% |
Accounts Receivable Turnover |
5.64 | 6.13 | 6.55 | 7.36 | 8.56 | 7.11 | 6.44 | 6.74 | 7.50 | 7.60 |
Accounts Payable Turnover |
23.64 | 17.38 | 9.85 | 8.48 | 9.16 | 7.31 | 6.91 | 7.13 | 7.06 | 7.04 |
Inventory Turnover |
3.21 | 3.51 | 3.33 | 3.56 | 3.96 | 3.43 | 3.48 | 3.52 | 3.97 | 3.69 |
Average Days of Payables |
16.87 | 13.72 | 28.40 | 45.58 | 43.66 | 42.39 | 55.42 | 49.13 | 48.22 | 67.13 |
Days of Inventory on Hand |
117.79 | 107.12 | 101.08 | 117.78 | 94.23 | 105.99 | 103.09 | 104.13 | 93.12 | 110.53 |
Average Receivables |
193.11 | 185.53 | 171.90 | 153.17 | 127.00 | 132.59 | 149.65 | 144.83 | 138.81 | 115.99 |
Average Payables |
20.86 | 28.95 | 50.86 | 59.25 | 50.87 | 54.18 | 59.47 | 58.98 | 65.80 | 54.26 |
Average Inventory |
153.42 | 143.21 | 150.42 | 141.23 | 117.65 | 115.49 | 117.95 | 119.21 | 117.08 | 103.44 |
Average Assets |
3,448.27 | 3,360.32 | 3,336.07 | 3,512.21 | 3,549.98 | 3,471.59 | 3,477.47 | 3,600.82 | 3,835.98 | 3,430.07 |
Average Common Equity |
1,861.21 | 1,744.99 | 1,551.08 | 1,512.35 | 1,467.95 | 1,264.63 | 1,133.40 | 1,137.22 | 1,000.58 | 783.44 |
Columns are period end dates